Selected Grants
Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029The Southeastern Liver Health Cohort Study
ResearchCo Investigator · Awarded by North Carolina State University · 2023 - 2027Lipid Metabolite Profiles and Cardiovascular Events in Persons with HIV (PWH) who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ResearchSignificant Contributor · Awarded by American College of Gastroenterology · 2024 - 2027Duke Training Grant in Digestive Diseases and Nutrition
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2027A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease
Clinical TrialPrincipal Investigator · Awarded by Ultragenyx Pharmaceutical · 2022 - 2027Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029The Southeastern Liver Health Cohort Study
ResearchCo Investigator · Awarded by North Carolina State University · 2023 - 2027Lipid Metabolite Profiles and Cardiovascular Events in Persons with HIV (PWH) who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ResearchSignificant Contributor · Awarded by American College of Gastroenterology · 2024 - 2027Duke Training Grant in Digestive Diseases and Nutrition
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2027A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease
Clinical TrialPrincipal Investigator · Awarded by Ultragenyx Pharmaceutical · 2022 - 2027Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026Long-term safety and tolerability study of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis.
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2023 - 2026A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Clinical TrialPrincipal Investigator · Awarded by Dicerna Pharmaceuticals, Inc. · 2023 - 2026A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Company · 2022 - 2025ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Clinical TrialPrincipal Investigator · Awarded by CymaBay Therapeutics · 2021 - 2025Abbreviated MRI for HCC screening in cirrhotic patients
ResearchCo Investigator · Awarded by Icahn School of Medicine at Mount Sinai · 2020 - 2025A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic A
Clinical TrialPrincipal Investigator · Awarded by GENFIT · 2021 - 2025A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2022 - 2025A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC)
Clinical TrialPrincipal Investigator · Awarded by Pliant Therapeutics, Inc. · 2023 - 2024GS-US-428-4194
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2019 - 2024Quantifying Enteric Metabolism of Branched-chain Amino Acids in Relation to Other Dietary and Microbiota Nutrients
ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2023The Southeastern Liver Health Cohort Study
ResearchCo Investigator · Awarded by North Carolina State University · 2021 - 2023RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Clinical TrialPrincipal Investigator · Awarded by CymaBay Therapeutics · 2021 - 2023CymaBay CB8025-31735
Clinical TrialPrincipal Investigator · Awarded by CymaBay Therapeutics · 2019 - 2022Novartis - AMBER - VAY736
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2021Medical Student Research Training Supplement
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2021HBV Clinical Research Network Site Application_Subcontract to UNC
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2015 - 2021The Impact of Race, Ethnicity, and Socioeconomic Status on Listing for Liver Transplant after Referral
ResearchMentor · Awarded by American Association for the Study of Liver Diseases · 2018 - 2020Sulfasalazine in PSC
Clinical TrialPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2018 - 2020Heart/Lung Transplant Study
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020Gilead 428-4025 - A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2017 - 2020The purpose of this study is to evaluate the use of passive, wirelessly observed therapy (WOT) using Proteus Discover¿ for maintaining HCV treatment adherence and achieving viral titer suppression in HCV-infected patients.
Clinical TrialPrincipal Investigator · Awarded by Proteus Digital Health, Inc. · 2017 - 2020Smart-C - A phase IIIb open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecapevir (300 gm)/pibrentasvis (120mg) in chronic HCV treatment naive patients without cirrhosis.
Clinical TrialPrincipal Investigator · Awarded by The Kirby Institute · 2018 - 2019Gilead 427-4024..A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2017 - 2019TaiwanJ JKB 122AIH...A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients Who Are Refractory or Intolerant to Current Therapies
Clinical TrialPrincipal Investigator · Awarded by TaiwanJ Pharmaceuticals Co. Ltd · 2015 - 2019RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2013 - 2019An Observational Cohort Study of the Use of Avatrombopag in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure
ResearchPrincipal Investigator · Awarded by DOVA Pharmaceuticals · 2018 - 2019A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Clinical TrialPrincipal Investigator · Awarded by University of Florida · 2017 - 2019A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Child-Pugh-Turcotte Class Cirrhosis
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2017 - 2019A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals, Inc. · 2015 - 2019Abbvie M13-596 A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2016 - 2019Gilead 337-1746 ¿A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2015 - 2018The Impact of Increasing Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients
FellowshipCo-Mentor · Awarded by American Association for the Study of Liver Diseases · 2017 - 2018MK-3682 PN011 A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regime of MK-5172 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2 and GT4 Infection "C-CREST 1"
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2015 - 2017AbbVie M14-868 A Randomized, Open-label multicenter study to evaluate the efficacy, safety, and pharmacokinetics of co-administration of ABT-493 and ABT-530 with and without RBV in subjects with chronic hepatitis C virus (HCV) Genotype 2 or Genotype
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2014 - 2017Merck MK-5172-017-02 A long-term follow-up study to evaluate the durability of Viro-Logic response and/or viral resistance patterns of subjects with Chronic Hepatitis C who have been previously treated with MK-5172 in a prior clinical trial.
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2015 - 2017Regulation of T cell exhaustion by microRNA-720
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2017NGM 14-0104
Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals · 2014 - 2017Merck/MSD MK-5172-065-00
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2014 - 2017A Phase 2 open-label study in patients with recurrent Genotype 1 Hepatitis
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2017GS-US-342-1137
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2014 - 2017Evidera PSC
Clinical TrialPrincipal Investigator · Awarded by Evidera · 2014 - 2016BMS Muir, AI443-113
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015BMS AI443-102-0016 A Phase 3 Evaluation
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015HPN-100-022
Clinical TrialPrincipal Investigator · Awarded by Hyperion Biotechnology, Inc. · 2014 - 2015Pilot Study to Assess Changes in Immuneregulation with Phase of Chronic HBV Infection and Antiviral Therapy
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2013 - 2015Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients
ResearchCo-Mentor · Awarded by National Institutes of Health · 2011 - 2015VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
ResearchSenior Investigator · Awarded by National Institutes of Health · 2014 - 2015Patient self-management and gene guided therapy for CHC
ResearchCo Investigator · Awarded by National Institutes of Health · 2012 - 2015A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2013 - 2014Gilead GS-US-334-0107 LOI
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2012 - 2012Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2008 - 2011Uncertainity and Watchful Waiting in Chronic Hepatitis C
ResearchCo Investigator · Awarded by National Institutes of Health · 2005 - 2009Interferon-y for the treatment of chronic HCV infection
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2004External Relationships
- Cymabay
- Gilead Sciences, Inc.
- Ultragenyx
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.